Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Overview of Silence Therapeutics Plc
Silence Therapeutics Plc is a biotechnology company that harnesses the body’s natural RNA interference (RNAi) mechanism to deliver novel therapeutic solutions. At its core, the company leverages siRNA technology to inhibit the production of disease-causing proteins by selectively silencing specific genes, thereby revolutionizing the approach to treating several life-threatening conditions. The company utilizes its proprietary mRNAi GOLD platform to develop and refine its drug candidates, ensuring precision in targeting disease pathways with enhanced molecule stability and effective delivery to desired cell populations. This innovative approach underscores the company’s commitment to advancing therapeutic interventions using breakthrough RNAi technology.
Core Business Areas and Technology
Silence Therapeutics is built around a sophisticated scientific framework that integrates both proprietary RNA chemistries and delivery systems. By designing therapeutic molecules that are tailored to be selectively delivered only to their target cells, the company has set a new standard in the development of RNA-based therapies. The emphasis on a customizable modular technology platform allows the venture to explore a wide range of therapeutic possibilities, which includes internal development as well as strategic out-licensing initiatives with third-party collaborators. Within its robust portfolio, key scientific innovations are applied to enhance the stability, specificity, and overall therapeutic effectiveness of their siRNA candidates.
Therapeutic Focus and Pipeline
The company’s pipeline underscores its dedication to addressing several critical medical conditions. It focuses primarily on three major therapeutic areas: cardiovascular disease, hematology, and rare diseases. Each of these areas benefits from an in-depth understanding of disease mechanisms and a commitment to translational research. The product candidates in the pipeline are developed with a view to intervene at the molecular level, precisely targeting the genetic components responsible for disease pathology. This detailed and science-driven approach not only enhances the potential for successful treatment outcomes but also positions Silence Therapeutics as a thoughtful innovator within a competitive biopharma landscape.
Competitive Landscape and Differentiation
Silence Therapeutics operates in a highly specialized segment of the biotech industry where precision and specificity are paramount. In a field populated by various research initiatives and emerging technologies, the company distinguishes itself through its modular RNAi platform and specialized delivery mechanisms. Unlike traditional therapeutic approaches, its methodology is built on a foundation of precise gene targeting and robust molecular stability. This ability to specifically silence disease-causing genes, while minimizing off-target effects, provides a clear competitive edge that is grounded in tangible scientific advantages rather than speculative projections.
Operational and Strategic Insights
From an operational standpoint, Silence Therapeutics adopts a dual strategy that balances internal pipeline development with collaboration and out-licensing opportunities. This approach not only facilitates a diverse revenue model but also fosters partnerships that enable cross-disciplinary innovation. The company’s continual focus on refining its RNA interference technology demonstrates a commitment to enhancing treatment specificity and efficacy. Such an approach ensures that each therapeutic candidate is developed with a thorough understanding of underlying biological mechanisms and is positioned to address critical gaps in current medical treatments.
Scientific and Industry Terminology
The language used to describe the company's operations is firmly rooted in industry-specific terminology, such as 'RNA interference', 'siRNA', 'mRNAi GOLD platform', and 'gene silencing'. These terms are pivotal in conveying a deep level of expertise and indicate that the company’s therapies are developed with a meticulous approach to molecular biology and drug development. The technical precision in the description reflects the company's commitment to scientific robustness while ensuring that complex concepts are presented in an accessible manner to informed stakeholders.
Market Position and Business Model
Situated within a challenging and rapidly evolving biopharmaceutical landscape, Silence Therapeutics Plc is recognized for its innovative contributions in therapeutics development. Its business model emphasizes a research-intensive approach complemented by strategic collaborations, catering to both the internal development of novel therapies and the licensing of its technology. While avoiding speculative commentary about future performance, the company is positioned as an essential player within its niche, connecting rigorous scientific research with pragmatic therapeutic applications that address substantial unmet medical needs.
Conclusion
In summary, Silence Therapeutics Plc represents a comprehensive and technology-driven approach to modern medicine. By leveraging advanced RNA interference mechanisms to develop highly targeted siRNA therapies, the company has carved out a distinct niche in biotech research and therapeutic development. The integrated strategy of innovation, precision, and collaboration is central to its operations, positioning it as a knowledgeable and authoritative source in the field of targeted gene silencing therapies. Investors and interested stakeholders will find in Silence Therapeutics a detailed narrative of scientific endeavor complemented by strategic market positioning.
Silence Therapeutics (NASDAQ:SLN) filed a routine Form 8-K disclosing voting results from its 26 June 2025 Annual General Meeting. Shareholders approved all 13 resolutions, including the re-appointment of directors David Lemus, Tim McInerney, Iain Ross and Craig Tooman; an annual non-binding say-on-pay vote; ratification of PricewaterhouseCoopers LLP as both U.S. and U.K. auditors; adoption of the 2024 U.K. statutory accounts; and replacement of the company’s articles of association. Support levels exceeded 90% for most items (e.g., Craig Tooman re-elected with 78.23 M votes for vs. 28.4 k against). The board will continue to seek shareholder input on executive compensation annually. No other material business, strategic changes or financial disclosures were announced.
Silence Therapeutics Plc (SLN) – Schedule 13D/A Amendment No. 9
The filing discloses the updated beneficial ownership of long-time shareholder Richard Ian Griffiths and several Jersey-based entities he controls. After recent open-market activity and an increase in the company’s share capital, Mr. Griffiths now reports 34,543,302 ordinary shares (held directly and through seven entities), representing 24.4 % of SLN’s 141,690,849 outstanding shares. Voting and dispositive power for all shares is held solely by Mr. Griffiths.
Recent transactions: Between 8 May 2025 and 24 Jun 2025, Mr. Griffiths purchased an additional 543,581 ADSs on the open market for a combined cash consideration of US $2.7 million; each ADS equals three ordinary shares. These purchases were funded with personal or affiliated-company cash.
Entity breakdown:
- Ora Capital Ltd – 19,221,525 ordinary shares (13.6 %)
- Sarossa Plc – 1,815,522 shares
- Cream Capital Ltd – 3,967,896 shares
- Blake Holdings Ltd – 300,000 shares
- Ora Ventures Ltd – 360,000 shares
- Pinkey’s Ltd – 190,500 shares
- Direct holding – 8,687,859 shares
The amendment notes that the percentage ownership has changed because of both the incremental ADS purchases and dilution stemming from a recent increase in the Issuer’s share capital. No new contracts, voting agreements or other material relationships were reported, and a standard joint-filing agreement is included as an exhibit.
Silence Therapeutics plc (SLN) – Form 4 insider transaction. 10% owner Richard Ian Griffiths reported a series of open-market purchases of the company’s American Depositary Shares (ADSs) between 22 and 24 June 2025.
- Griffiths bought 20,977 ADS at $5.84 on 22 Jun, 35,005 ADS at $5.88 on 23 Jun and 26,624 ADS at $6.12 on 24 Jun, totalling 82,606 ADS.
- At the stated prices, the aggregate consideration is approximately US $0.49 million.
- Each ADS represents three ordinary shares; the purchases therefore add about 247,818 ordinary shares to the insider’s economic exposure.
- Following the transactions, Griffiths’ direct holding increased to 11,514,434 ADS, equivalent to roughly 34.5 million ordinary shares, consolidating his status as a 10%+ shareholder.
- All transactions are coded “P” (open-market buy) and were made directly, with no derivative features other than the standard ADS-to-ordinary-share convertibility.
Insider buying by a large, long-term holder is typically interpreted as a positive sentiment signal, suggesting management or significant shareholders view current valuation as attractive. However, the dollar amount, while meaningful, is modest relative to the insider’s existing position, limiting immediate balance-sheet impact.
Silence Therapeutics plc (SLN) – Form 4 insider purchase
On 17 and 18 June 2025, 10% shareholder Richard Ian Griffiths disclosed open-market purchases totaling 70,448 American Depositary Shares (ADS), coded “P”. The transactions were executed at $5.29 and $5.69 per ADS, representing an estimated cash outlay of roughly $0.39 million.
Because each ADS is immediately convertible into three ordinary shares at no additional cost, the buys expand Griffiths’ economic exposure by about 211,344 ordinary shares. His directly held ADS position rose from 11,392,779 to 11,431,828.
The filing did not reference a Rule 10b5-1 trading plan, suggesting discretionary purchases. No insider sales or derivative exercises were reported.
For investors, clustered insider buying by a large, long-tenured holder often serves as a constructive sentiment indicator, especially when executed near multi-year lows (price context not specified in the filing). While modest relative to Griffiths’ total stake, the fresh capital deployment may signal confidence in Silence Therapeutics’ valuation and forthcoming catalysts.
FAQ
What is the current stock price of Silence Therapeutics Plc (SLN)?
What is the market cap of Silence Therapeutics Plc (SLN)?
What is the primary focus of Silence Therapeutics Plc?
How does the company utilize its mRNAi GOLD platform?
What distinguishes Silence Therapeutics from other biotech companies?
Which therapeutic areas are addressed by Silence Therapeutics?
How does the company generate revenue?
How is gene silencing achieved by their technology?
What role do collaborations play in the company’s strategy?
How does the company maintain specificity in its treatment approach?
